{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:35:11Z","timestamp":1791815711796,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Real-world evidence on the potential of tyrosine kinase inhibitors (TKIs) for dementia and Parkinson\u2019s Disease (PD) is crucial. This observational study aimed to evaluate TKIs, particularly nilotinib and imatinib, as potential therapeutic agents for these conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective cohort study, 5,579 cancer patients who were prescribed TKIs (users; \u2265 40\u202fyears) within 5\u202fyears were used, while propensity score-matched patients without any record of TKIs (never users) served as the reference. An association of TKIs with dementia and PD was assessed by the Fine-Gray Model with adjusted-competitive hazard ratios (aCHRs) and 95% confidence intervals (CIs): [aCHRs (95% CIs; <jats:italic>p<\/jats:italic>-value)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The risk of dementia decreased when all types of TKIs [0.65 (0.48\u20130.88; &amp;lt;0.01)], imatinib [0.66 (0.48\u20130.89; &amp;lt;0.01)], and nilotinib [0.46 (0.23\u20130.93; &amp;lt;0.05)] was used in cancer patients. Additionally, the reduced risk of PD was identified in users of all [0.56 (0.33\u20130.97; &amp;lt;0.05)] and imatinib [0.55 (0.32\u20130.96; &amp;lt;0.05)]. When the risk was evaluated according to the number of times for total usage, the aCHRs for PD in the low, middle, and high-frequency groups were 0.46 (0.20\u20131.02), 0.78 (0.40\u20131.54), and 0.40 (0.15\u20131.05), respectively. The risk of dementia was 0.68 (0.46\u20130.99), 0.57 (0.36\u20130.90), and 0.71 (0.44\u20131.17) in order of frequency (from low to high).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>As an observational study indicated a decreased risk of dementia and PD with long-term TKI use, imatinib and nilotinib may serve as potential therapeutic agents for these conditions, with more evidence from rigorous clinical trials to validate.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1628876","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:03:42Z","timestamp":1756274622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Nilotinib and imatinib: potential candidates for treatment of dementia and Parkinson\u2019s disease through national health insurance data"],"prefix":"10.3389","volume":"16","author":[{"given":"Jihun","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A review of computational drug repurposing","volume":"27","author":"Park","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s43587-021-00138-z","article-title":"Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer\u2019s disease","volume":"1","author":"Fang","year":"2021","journal-title":"Nat Aging"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/aian.AIAN_177_18","article-title":"Anticancer drugs for Parkinson's disease: is it a ray of hope or only hype?","volume":"22","author":"Dash","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.25775","article-title":"Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer's disease","volume":"88","author":"Turner","year":"2020","journal-title":"Ann Neurol"},{"key":"ref8","volume-title":"Towards a dementia plan: a WHO guide","year":"2018"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1192\/bjp.bp.111.101931","article-title":"Affective disorders and risk of developing dementia: systematic review","volume":"202","author":"da Silva","year":"2013","journal-title":"Br J Psychiatry"},{"key":"ref10","volume-title":"Parkinson disease: A public health approach: Technical brief","year":"2022"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/JEP.S265626","article-title":"Review of advanced drug trials focusing on the reduction of brain beta-amyloid to prevent and treat dementia","volume":"14","author":"Decourt","year":"2022","journal-title":"J Exp Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JPD-229002","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2022 update","volume":"12","author":"McFarthing","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/mds.28389","article-title":"Long-term safety and clinical effects of Nilotinib in Parkinson's disease","volume":"36","author":"Pagan","year":"2021","journal-title":"Mov Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced Parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e016640","DOI":"10.1136\/bmjopen-2017-016640","article-title":"Cohort profile: the national health insurance service-national health screening cohort (NHIS-HEALS) in Korea","volume":"7","author":"Seong","year":"2017","journal-title":"BMJ Open"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/ije\/dyv319","article-title":"Cohort profile: the national health insurance service\u2013national sample cohort (NHIS-NSC), South Korea","volume":"46","author":"Lee","year":"2017","journal-title":"Int J Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3904\/kjim.2021.158","article-title":"Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3340\/jkns.2021.0195","article-title":"The relationship between Parkinson\u2019s disease and acute myocardial infarction in Korea: a nationwide longitudinal cohort study","volume":"65","author":"Sheen","year":"2022","journal-title":"J Korean Neurosurg Soc"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-023-00462-8","article-title":"A nationwide cohort study on diabetes severity and risk of Parkinson disease","volume":"9","author":"Han","year":"2023","journal-title":"NPJ Parkinson's Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jpsychires.2019.08.010","article-title":"Effect of drug compliance on health care costs in newly-diagnosed dementia: analysis of nationwide population-based data","volume":"118","author":"Oh","year":"2019","journal-title":"J Psychiatr Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s12603-017-0914-3","article-title":"Dementia and death after stroke in older adults during a 10-year follow-up: results from a competing risk model","volume":"22","author":"Kim","year":"2018","journal-title":"J Nutr Health Aging"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"djv366","DOI":"10.1093\/jnci\/djv366","article-title":"Performing survival analyses in the presence of competing risks: a clinical example in older breast cancer patients","volume":"108","author":"de Glas","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.canep.2017.11.003","article-title":"Seasonal trends of diagnosis of childhood malignant diseases and viral prevalence in South Korea","volume":"51","author":"Shim","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.3390\/jcm10204774","article-title":"Clinical efficacy of ruxolitinib in patients with myelofibrosis: a nationwide population-based study in Korea","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-014-0073-2","article-title":"Alpha-synuclein biology in Lewy body diseases","volume":"6","author":"Kim","year":"2014","journal-title":"Alzheimer's Res Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum Mol Genet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging \u03b2-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbrc.2012.10.129","article-title":"Soluble oligomers and fibrillar species of amyloid \u03b2-peptide differentially affect cognitive functions and hippocampal inflammatory response","volume":"429","author":"He","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/emmm.201302771","article-title":"Tyrosine kinase inhibition increases functional parkin-B eclin-1 interaction and enhances amyloid clearance and cognitive performance","volume":"5","author":"Lonskaya","year":"2013","journal-title":"EMBO Mol Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00109-013-1112-3","article-title":"Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance","volume":"92","author":"Lonskaya","year":"2014","journal-title":"J Mol Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","article-title":"Role of tau protein in both physiological and pathological conditions","volume":"84","author":"Avila","year":"2004","journal-title":"Physiol Rev"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/humu.20086","article-title":"The role of tau (MAPT) in frontotemporal dementia and related tauopathies","volume":"24","author":"Rademakers","year":"2004","journal-title":"Hum Mutat"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.30654\/MJPS.10025","article-title":"Investigating the potential of Nilotinib and its derivatives in targeting tau protein hyperphosphorylation for Alzheimer's disease treatment","volume":"7","author":"Hajihassan","year":"2023","journal-title":"Mathews J Pharma Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.4149\/neo_2021_201126N1282","article-title":"Nilotinib, a discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer","volume":"68","author":"Yu","year":"2020","journal-title":"Neoplasma"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2017.07.009","article-title":"Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models","volume":"311","author":"Hebron","year":"2017","journal-title":"J Neuroimmunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1093\/hmg\/ddaa177","article-title":"Discoidin domain receptor 1 is a therapeutic target for neurodegenerative diseases","volume":"29","author":"Fowler","year":"2020","journal-title":"Hum Mol Genet"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jns.2018.06.005","article-title":"Tau clearance improves astrocytic function and brain glutamate-glutamine cycle","volume":"391","author":"Hebron","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref40","first-page":"69","volume-title":"Tau protein-targeted therapies in Alzheimer\u2019s disease: current state and future perspectives","author":"Pluta","year":"2020"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.neuroscience.2015.07.070","article-title":"Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer\u2019s disease models","volume":"304","author":"Lonskaya","year":"2015","journal-title":"Neuroscience"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4172\/2155-9899.1000259","article-title":"Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in \u03b1-synucleinopathy","volume":"5","author":"Hebron","year":"2014","journal-title":"J Clin Cell Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/onco.13944","article-title":"Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: a population-based, propensity score-matched cohort study","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.parkreldis.2023.105281","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease","volume":"108","author":"Walsh","year":"2023","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1628876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:03:46Z","timestamp":1756274626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1628876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":46,"alternative-id":["10.3389\/fneur.2025.1628876"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1628876","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1628876"}}